Lil­ly Asia Ven­tures co-leads $100M+ round for Chi­nese biotech and its late-stage lu­pus drug

Can a Chi­nese biotech de­liv­er the first new lu­pus drug in decades? A high-pro­file group of VCs are bet­ting on it.

Lil­ly Asia Ven­tures and Lake Bleu Cap­i­tal are the co-head­lin­ers for Re­meGen’s lat­est raise, which brought in more than $100 mil­lion. Hud­son Bay Cap­i­tal and Vi­vo Cap­i­tal — which, like LAV, al­so in­vest­ed in a pre-IPO round for Leg­end Biotech un­veiled to­day — chimed in, as did Jan­chor Part­ners and Or­biMed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER